TRAVERE THERAPEUTICS, INC. Business Acquisition, Pro Forma Earnings Per Share, Diluted
TRAVERE THERAPEUTICS, INC. (TVTX) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$0.90 per share for the 3-month period ending 2014-06-30, per its 10-Q filed 2014-08-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2014-08-14
- TRAVERE THERAPEUTICS, INC. business acquisition, pro forma earnings per share, diluted for the quarter ending 2014-06-30 was -$0.90.
- TRAVERE THERAPEUTICS, INC. business acquisition, pro forma earnings per share, diluted for the quarter ending 2013-06-30 was -$0.34.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 6 month |
|---|---|---|
| 2014-06-30 | -$0.90 10-Q · filed 2014-08-14 | -$2.51 10-Q · filed 2014-08-14 |
| 2013-06-30 | -$0.34 10-Q · filed 2014-08-14 | -$0.70 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |